E. Lee Ford-Jones
University of Toronto
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by E. Lee Ford-Jones.
Pediatric Blood & Cancer | 2006
Victoria Price; Sanjeev Dutta; Victor S. Blanchette; Sheila Butchart; Melanie Kirby; Jacob C. Langer; E. Lee Ford-Jones
Children born without a spleen or who have impaired splenic function, due to disease or splenectomy, are at significantly increased risk of life‐threatening bacterial sepsis. The mainstays of prevention are education, immunization, and prophylactic antibiotics. The availability of conjugate 7‐valent pneumococcal vaccines for use in children to age 9 years at least, as well as conjugate meningococcal C vaccine in some countries, for use beginning in infancy, appear to represent beneficial additions, but not substitutions, to previous recommendations for the use of polysaccharide 23‐valent pneumococcal and quadrivalent A, C, Y, W‐135 vaccines. Routine immunization against H. influenzae type b should continue with non‐immunized children older than age 5 years receiving two doses 2 months apart, similar to children who have not previously received conjugate pneumococcal vaccine in infancy. Annual influenza immunization, which reduces the risk of secondary bacterial infection, is also recommended for asplenic children and their household contacts. Many experts continue prophylaxis indefinitely although prophylaxis of the penicillin allergic child remains suboptimal.
Emerging Infectious Diseases | 2006
Shaun K. Morris; Jason Brophy; Susan E. Richardson; Richard C. Summerbell; Patricia C. Parkin; Frances Jamieson; Bill Limerick; Lyle Wiebe; E. Lee Ford-Jones
Clinicians in Ontario should be aware of symptoms and areas where disease is endemic.
Clinical Infectious Diseases | 2003
Marc H. Lebel; James D. Kellner; E. Lee Ford-Jones; Kyle Hvidsten; Edward C. Y. Wang; Vincent Ciuryla; Steve Arikian; Roman Casciano
The objective of this study was to evaluate the projected health benefits, costs, and cost-effectiveness of pneumococcal conjugate vaccination for infants and children aged <5 years in Canada. A health state model incorporating incidence, vaccine efficacy, costs, and transitional probabilities for the health states (well, meningitis, bacteremia, otitis media, pneumonia, and death) was constructed for a 10-year time horizon. Implementation of a pneumococcal conjugate vaccine program in Canada for each annual birth cohort of 340,000 persons observed over 10 years would be expected to save approximately 12 lives and 100,000 cases of pneumococcal disease over 10 years, resulting in total savings of
American Journal of Infection Control | 1990
Upton Allen; E. Lee Ford-Jones
67 million (Canadian dollars [Can
Journal of the Pediatric Infectious Diseases Society | 2016
Kim Zhou; Laura J. Sauvé; Susan E. Richardson; E. Lee Ford-Jones; Shaun K. Morris
]). Vaccination of healthy infants would result in net savings for society if the vaccine costs less than Can
Canadian Journal of Infectious Diseases & Medical Microbiology | 1993
Joanne M. Langley; E. Lee Ford-Jones; Derek C Armstrong; Ronald Gold; Stanley Read; Henry Levison
50 per dose. Moreover, for a vaccine purchase price of Can
JAMA Pediatrics | 1999
Rita Shahin; Ian L. Johnson; Frances Jamieson; Alison McGeer; Jonathan Tolkin; E. Lee Ford-Jones
67.50, infant vaccination would cost society Can
Pediatric Infectious Disease Journal | 2000
Valerie Waters; E. Lee Ford-Jones; Martin Petric; Margaret Fearon; Paul Corey; Rahim Moineddein
79,000 per life-year gained. Pneumococcal conjugate vaccination is a potentially cost-effective means of pneumococcal disease prevention.
JAMA Pediatrics | 1999
James D. Kellner; E. Lee Ford-Jones
Substantial progress has been made in measuring the burden of nosocomial infection in pediatric patients, particularly in certain populations (e.g., critical care, immunocompromised, chronic care, and patients with acquired immunodeficiency syndrome) and after certain procedures (e.g., central catheter lines and open-sternum cardiovascular surgery). Preventive measures, such as the use of goggles, gowns, and gloves, have been subjected to new and additional study. The following report is a summary of recent progress. A review of factors responsible for infection in various patient care populations and settings and recommendations for control are presented.
JAMA Pediatrics | 2000
E. Lee Ford-Jones; Elaine Wang; Martin Petric; Paul Corey; Rahim Moineddin; Margaret Fearon
We undertook a 28-year review of enteric fever at a large tertiary care pediatric center. Most cases occurred in children who visited friends and relatives in the Indian subcontinent, and there was significant antibiotic resistance. Documented vaccination rates were low, and many cases also had evidence of delays in diagnosis and treatment.